Skip to Content
Merck
All Photos(1)

Documents

D0565

Sigma-Aldrich

Digoxin-BSA bovine

lyophilized powder

Synonym(s):

Digoxin-BSA

Sign Into View Organizational & Contract Pricing


About This Item

MDL number:
UNSPSC Code:
12352202
NACRES:
NA.25

biological source

bovine

form

lyophilized powder

extent of labeling

~10 mol Digoxin per mol albumin

technique(s)

inhibition assay: suitable

UniProt accession no.

storage temp.

2-8°C

Gene Information

cow ... ALB(280717)

Application

Digoxin-BSA bovine is a cardioactive glycoside which can increase intracellular calcium concentration through Na+/K+-ATPase pump inhibition. Digoxin has been used in treatments of heart related disease and also studies of cancer treatments. It has shown the ability to inhibit prostate cancer cell growth, but has also shown a reduction in the efficiency of chemotherapy (reduced drug absorption) by increasing the amount of P-glycoprotein (Pgp).

Biochem/physiol Actions

Antigen-protein conjugate.

Physical form

Lyophilized from 0.06 M Tris

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

S P O'Neill et al.
Journal of immunology (Baltimore, Md. : 1950), 116(2), 363-366 (1976-02-01)
Animals immunized with hapten-protein conjugates subsequently circulate high concentrations of hapten bound by antibody. The levels of hapten detected are capable of significantly reducing antibody titer in the sera immunized animals. In the case of steroid-protein conjugates, the main source
Chiara Riganti et al.
Toxicology and applied pharmacology, 240(3), 385-392 (2009-08-04)
Digoxin and ouabain are cardioactive glycosides, which inhibit the Na+/K+-ATPase pump and in this way they increase the intracellular concentration of cytosolic calcium ([Ca2+](i)). They are also strong inducers of the P-glycoprotein (Pgp), a transmembrane transporter which extrudes several drugs
Elizabeth A Platz et al.
Cancer discovery, 1(1), 68-77 (2011-12-06)
Identification of novel indications for commonly prescribed drugs could accelerate translation of therapies. We investigated whether any clinically-used drugs might have utility for treating prostate cancer by coupling an efficient, high-throughput laboratory-based screen and a large, prospective cohort study. In
Y Ikeda et al.
Biological & pharmaceutical bulletin, 23(8), 906-910 (2000-08-30)
The preparation and antigenic properties of digoxin C-3' and C-3" hemisuccinate-bovine serum albumin (BSA) conjugates are described. The antisera were prepared by immunizing rabbits with each of the digoxin-BSA conjugates, and properties of the antisera were characterized by RIA with
Ioannis Prassas et al.
Molecular cancer therapeutics, 10(11), 2083-2093 (2011-08-24)
Cardiac glycosides (e.g., digoxin, digitoxin) constitute a diverse family of plant-derived sodium pump inhibitors that have been in clinical use for the treatment of heart-related diseases (congestive heart failure, atrial arrhythmia) for many years. Recently though, accumulating in vitro and

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service